MYELODYSPLASTIC SYNDROME

This study tested a drug called guadecitabine along with a donor white blood cell infusion in 55 adults whose leukemia or myelodysplastic syndrome came back after a stem cell transplant. The goal was to see if this combination could help the body fight the cancer again. The treat…

This study tested the drug ustekinumab in 8 people with a rare and severe form of intestinal Behçet's syndrome that also involves a blood disorder called myelodysplastic syndrome (MDS). The goal was to see if the drug could control gut symptoms and improve disease activity over 2…

This study tested whether adding pevonedistat to the standard drug azacitidine helps people with certain blood cancers live longer without their disease getting worse. It included 454 adults with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or low-blast…

This early-stage trial tested a combination of two drugs, ibrutinib and lenalidomide, in 4 people with myelodysplastic syndrome (MDS) who had not responded to or could not tolerate standard treatments. The main goal was to find the safest dose and understand side effects. The stu…

This study tested whether adding the drug itacitinib to standard medications (tacrolimus and sirolimus) could help prevent graft-versus-host disease (GVHD) in 59 people with blood cancers like leukemia or myelodysplastic syndrome who received a donor stem cell transplant. GVHD oc…

This early-phase trial tested a combination of a cancer vaccine (CDX-1401), an immune booster (poly ICLC), chemotherapy (decitabine), and an immunotherapy drug (nivolumab) in 8 people with myelodysplastic syndrome (MDS) or low-blast acute myeloid leukemia (AML). The main goal was…

This study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 29 adults with high-risk or returning acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after a donor stem cell transplant. The goal was to find the safest dose and see if the dr…

This study tested a two-step stem cell transplant for 62 people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor immune cells followed by a stem cell transplant. The goa…

This study tested different combinations of immune-suppressing drugs to prevent graft-versus-host disease (GVHD) in 174 patients with blood cancers who received a stem cell transplant from an unrelated donor. The goal was to find the most effective approach to reduce severe GVHD,…

This study tested a combination of two drugs, bortezomib and lenalidomide, in 22 adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) came back after a stem cell transplant. The main goal was to find the safest dose and see if the combo could reduce cancer …

This study tested whether adding 'off-the-shelf' natural killer (NK) immune cells from a donor could make stem cell transplants more effective for adults with high-risk forms of leukemia. The goal was to see if this combination was safe and could help prevent the cancer from comi…

This study looked at 126 adults aged 60 and older who had a bone marrow transplant for blood cancers like leukemia or lymphoma. Researchers measured physical and mental traits—like strength, memory, mood, and stress—to see which factors help people recover better. The goal was to…

This study tested a personalized geriatric optimization plan (GO!) in 30 patients aged 60 and older who were getting a stem cell transplant for blood cancers or bone marrow failure. The plan included tailored changes to diet, sleep, activity, and medications. The goal was to see …